At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 361 enrolled
Drug / intervention
Vortioxetine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects
In Brief
A Phase 4 clinical trial evaluating Vortioxetine, Paroxetine, and 1 other intervention for Healthy Volunteers. Completed, enrolled 361 participants across 15 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of vortioxetine (10 and 20 mg, once daily) versus paroxetine (20 mg, once daily) on sexual functioning in healthy participants after 5 weeks of double-blind treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartNov 2016
Primary CompletionMay 2017
Study CompletionJun 2017
TodayJul 2026
First PostedOct 13, 2016
Enrollment StartNov 21, 2016
Primary CompletionMay 31, 2017
Study CompletionJun 9, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.7 years ago
Interventions
Vortioxetinedrug
Vortioxetine Overencapsulated Tablet
Paroxetinedrug
Paroxetine Overencapsulated Tablets.
Placebodrug
Vortioxetine Placebo-matching Capsules.